Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexadecane SCHEMBL16712179 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TSHRTHRBLMNAMEN1 | |
| Octane SCHEMBL5960977 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TSHRTHRBLMNAMEN1 | |
| Decane SCHEMBL503047 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TSHRTHRBLMNAMEN1 | |
| Tert-Butyl Hydroperoxide SCHEMBL27266819 | 0.97 | ALDH1A1 (0.60) | ALDH1A1TSHRTHRBLMNAMEN1 | |
| Tert-Butyl Hydroperoxide SCHEMBL28247696 | 0.90 | ALDH1A1 (0.60) | ALDH1A1TSHRTHRBLMNAMEN1 | |
| Tert-Butyl Hydroperoxide SCHEMBL27389585 | 0.83 | ALDH1A1 (0.69) | ALDH1A1TSHR | |
| Tert-Butyl Hydroperoxide SCHEMBL8125721 | 0.82 | ALDH1A1 (0.61) | ALDH1A1TSHRTHRBLMNAMEN1 | |
| Heptanoate SCHEMBL27428584 | 0.82 | GPR84 (0.71) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Dodecanoate SCHEMBL27278835 | 0.82 | GPR84 (0.71) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Tert-Butyl Hydroperoxide SCHEMBL8131481 | 0.80 | ALDH1A1 (0.47) | ALDH1A1TSHRTHRBLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124379-A1 | HYDROXYLATION OF ALKANES USING OZONE | UNIVERSITY OF KANSAS | 2024-04-18 | — | — | US | disclosed |
| EP-3296306-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2022-11-09 | — | — | EP | disclosed |
| CN-108473526-B | Process for producing oligonucleotide and nucleoside, nucleotide or oligonucleotide | 味之素株式会社 | 2022-08-09 | — | — | CN | disclosed |
| EP-4006045-A1 | NUCLEIC ACID COMPOUND MANUFACTURING METHOD AND NUCLEIC ACID COMPOUND | FUJIFILM Corporation (JP) | 2022-06-01 | — | — | EP | disclosed |
| CN-113717239-A | Precipitation accelerator and precipitation method using the same | 味之素株式会社 | 2021-11-30 | — | — | CN | disclosed |
| CN-107207555-B | Precipitation accelerator and precipitation method using the same | 味之素株式会社 | 2021-10-22 | — | — | CN | disclosed |
| EP-2816053-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2021-03-24 | — | — | EP | disclosed |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | AJINOMOTO CO., INC. (JP) | 2021-02-16 | — | — | US | disclosed |
| CN-106977567-B | Oligonucleotide with protected base moiety | 味之素株式会社 | 2021-02-02 | — | — | CN | disclosed |
| US-10464966-B2 | Precipitation promoter and precipitation method in which same is used | AJINOMOTO CO., INC. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-2816053-A1 | BASE-PROTECTED OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-8846885-B2 | Oligonucleotide with protected base | AJINOMOTO CO., INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2711370-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20130267697-A1 | OLIGONUCLEOTIDE WITH PROTECTED BASE | AJINOMOTO CO., INC. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2012-11-22 | — | — | US | disclosed |
| CN-1269808-C | Process for the preparation of vialoguestamin D analogs | HOFFMANN LA ROCHE (CH) | 2006-08-16 | — | — | CN | disclosed |
| CN-1179938-C | Process for preparing vitamin D analogues | - | 2004-12-15 | — | — | CN | disclosed |
| CN-1554650-A | Process for the preparation of vialoguestamin d analogs | - | 2004-12-15 | — | — | CN | disclosed |
| CN-1287115-A | Process for preparing vitamin D analogues | HOFFMANN LA ROCHE (CH) | 2001-03-14 | — | — | CN | disclosed |
| US-4921962-A | REACTION OF AMINE WITH HYDROPEROXIDE | CIBA-GEIGY CORPORATION (US) | 1990-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | POLL, POLM, NUDT1 | ALDH1A1 1780/4885TSHR 2269/4885THRB 3036/4885 |
| US-10464966-B2 | Precipitation promoter and precipitation method in which same is used | SP1, MED25, CTCF | ALDH1A1 2282/4885TSHR 3627/4885THRB 3519/4885 |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | RNGTT, POLM, RNMT | ALDH1A1 4056/4885TSHR 1572/4885THRB 1803/4885 |
| US-20130267697-A1 | OLIGONUCLEOTIDE WITH PROTECTED BASE | POLRMT, POLN, RNGTT | ALDH1A1 4072/4885TSHR 2943/4885THRB 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.